ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China

Shi, Yuequan; Fang, Jian; Zhou, Chengzhi; Liu, Anwen; Wang, Yan; Meng, Qingwei; Ding, Cuimin; Ai, Bin; Gu, Yangchun; Yao, Yu; Sun, Hong; Guo, Hui; Zhang, Cuiying; Song, Xia; Li, Junling; Xu, Bei; Han, Zhiqiang; Song, Meijun; Tang, Tingyu; Chen, Peifeng; Lu, Hongmin; Shui, Yongjie; Lou, Guangyuan; Zhang, Dongming; Liu, Jia; Liu, Xiaoyan; Liu, Xiangning; Gao, Xiaoxing; Zhou, Qing; Chen, Minjiang; Zhao, Jing; Zhong, Wei; Xu, Yan; Wang, Mengzhao*复旦大学; 广州医学院; 北京大学; 南昌大学; 上海交通大学; 哈尔滨医科大学; 河北医科大学; 浙江大学; 西安交通大学; 中国医学科学院; 中国科学院研究生院; 中国医学科学院北京协和医院; 1
Thoracic Cancer2022-2DOI: 10.1111/1759-7714.14274
15被引9阅读
引用收藏
分享

摘要

Background Immune checkpoint inhibitors (ICIs) are the standard treatment for advanced lung cancer, but immune-related adverse events (irAEs) remain poorly understood, especially in a real-world setting. Methods A multicenter observational study was conducted. Medical records of lung cancer patients treated with ICIs at 26 hospitals from January 1, 2015, to February 28, 2021, were retrieved. Types of ICIs included antiprogrammed cell death 1 or antiprogrammed cell death ligand 1 (PD-L1) monotherapy, anticytotoxic T-lymphocyte antigen-4 monotherapy, or combination therapy. Results In total, 1905 patients with advanced lung cancer were evaluated. The median age was 63 (range 28-87) years, and the male/female ratio was 3.1:1 (1442/463). The primary histological subtype was adenocarcinoma (915). A total of 26.9% (512/1905) of the patients developed 671 irAEs, and 5.8% (110/1905) developed 120 grade 3-5 irAEs. Median duration from ICI initiation to irAEs onset was 56 (range 0-1160) days. The most common irAEs were thyroid dys7.2%, 138/1905), pneumonitis (6.5%, 124/1905), and dermatological toxicities (6.0%, 115/1905). A total of 162 irAEs were treated with steroids and 11 irAEs led to death. Patients with positive PD-L1 expression (>= 1%) and who received first-line ICI treatment developed more irAEs. Patients who developed irAEs had a better disease control rate (DCR, 71.3% [365/512] vs. 56.0% [780/1145]; p < 0.001). Conclusions The incidence rate of irAEs was 26.9% in a real-world setting. IrAEs might be related to a better DCR, but clinicians should be more aware of irAE recognition and management in clinical practice.

学科与关键词

关键词
advanced lung cancerimmune checkpoint inhibitorsimmune-related adverse eventsreal-world data
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Thoracic Cancer
发表日期
2022-02
卷期
第 13 卷, 第 3 期
页码
412-422
DOI
10.1111/1759-7714.14274
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
Merk Co., Ltd.

作者

  • S

    Shi, Yuequan (第一作者)

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • F

    Fang, Jian

    2 · peking univ canc hosp & inst

查看全部 34 位作者收起作者
  • Z

    Zhou, Chengzhi

    1 · guangzhou med univ

  • L

    Liu, Anwen

    2 · nanchang univ

  • W

    Wang, Yan

    chinese acad med sci · peking union med coll

  • M

    Meng, Qingwei

    harbin med univ

  • D

    Ding, Cuimin

    hebei med univ

  • A

    Ai, Bin

    beijing hosp · chinese acad med sci

  • G

    Gu, Yangchun

    peking univ

  • Y

    Yao, Yu

    1 · xi an jiao tong univ

  • S

    Sun, Hong

    1 · xi an jiao tong univ

  • G

    Guo, Hui

    1 · xi an jiao tong univ

  • Z

    Zhang, Cuiying

  • S

    Song, Xia

    shanxi prov canc hosp

  • L

    Li, Junling

    chinese acad med sci · peking union med coll

  • X

    Xu, Bei

    fudan univ

  • H

    Han, Zhiqiang

  • S

    Song, Meijun

    zhejiang prov peoples hosp

  • T

    Tang, Tingyu

    zhejiang hosp · zhejiang univ

  • C

    Chen, Peifeng

  • L

    Lu, Hongmin

    shanghai jiao tong univ

  • S

    Shui, Yongjie

    2 · zhejiang univ

  • L

    Lou, Guangyuan

    univ chinese acad sci · zhejiang canc hosp

  • Z

    Zhang, Dongming

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • L

    Liu, Jia

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • L

    Liu, Xiaoyan

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • L

    Liu, Xiangning

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • G

    Gao, Xiaoxing

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • Z

    Zhou, Qing

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • C

    Chen, Minjiang

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • Z

    Zhao, Jing

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • Z

    Zhong, Wei

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • X

    Xu, Yan

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • W

    Wang, Mengzhao (通讯)

    chinese acad med sci · peking union med coll · peking union med coll hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417